Influenza and Pneumococcal Vaccination Uptake among Canadian Adults: Insights from the CLSA

Dr. Nicole E. Basta, PhD MPhil Associate Professor and MSc Epidemiology Program Director Department of Epidemiology, Biostatistics, and Occupational Health, McGill University Canada Research Chair in Infectious Disease Prevention (Tier 2)

CLSA Webinar - June 7, 2023

😻 McGill

Today's Seminar



Influenza and Pneumonia: A Significant Cause of Death among Older Adults

Rank of Influenza/Pneumonia among the Leading Causes of Death in Canada

65-74 yrs old	Rank
2015	8 th
2016	8 th
2017	8 th
2018	8 th
2019	8 th
2020	9 th

75-84 yrs old	Rank
2015	7 th
2016	8 th
2017	8 th
2018	7 th
2019	8 th
2020	10 th

<u>></u> 85 yrs old	Rank
2015	5 th
2016	7 th
2017	6 th
2018	4 th
2019	7 th
2020	8 th

Source: Statistics Canada https://www150.statcan.gc.ca



Healthy Aging: Prevention of Infectious Diseases to Prevent Morbidity

Canadian adults ages 65+ had the highest cumulative rates of influenza-associated hospitalization:132/100,000





Source: National Foundation for Infectious Diseases

4

Who is at Risk of Severe Influenza and Pneumococcal?



Older Adults 65+

Adults age 65 years and older are at greater risk of flu-related complications, in part because of weakened immune systems

People with Certain Chronic Health Conditions



Heart disease patients are 6 times more likely to have a heart attack within 7 days of influenza infection



Lung disease (including asthma and/or COPD):

Flu can increase inflammation in the lungs and airways, which can trigger asthma attacks and make COPD symptoms worse

Diabetes:

Diabetes can interfere with the body's ability to fight flu, and flu infection can interfere with management of blood sugar levels



Obesity:

Individuals with a body mass index (BMI) of 40+ have a higher rate of serious flu-related complications, including hospitalization

8

Compromised immune system:

People who have weakened immune systems, including current and former cancer patients and those living with HIV/AIDS, are at higher risk of developing serious flu-related complications, including hospitalization and death

Source: National Foundation for Infectious Diseases

See the National Advisory Committee on Immunization (NACI) for a complete list of chronic health conditions that increase risk



nicole.basta@mcgill.ca

5

Vaccination: A Cornerstone of Prevention that Supports Healthy Aging

Influenza Vaccination

- Designed to protect against multiple flu strains
- Reduces the risk of infection, illness, servere illness, hospitalization & death
- Annual vaccination required

Pneumococcal Vaccination

- Two vaccines were available PNEU-P-23 and PNEU-C-13 at the time of our study
- Both protect against multiple pneumococcal bacterial serotypes
- Reduces the risk of invasive pneumococcal disease, hospitalization, and death caused by these strains



Evidence has demonstrated that both influenza and pneumococcal vaccination are safe, and they are the most effective way to prevent severe outcomes from these diseases.

Current Vaccination Recommendations: Canada

Influenza Vaccination

NACI particularly recommends that everyone at high risk of severe outcomes be vaccinated annually at the start of the flu season, including:

- adults aged 65 years and older AND
- all adults with chronic medical conditions

Pneumococcal Vaccination

At the time of our study (2015-2018)*, NACI recommended that:

- adults aged 65 years and older receive one dose of PNEU-P-23 AND
- all adults with certain chronic medical conditions receive one dose of both PNEU-P-23 and PNEU-C-13

*In 2023, NACI updated recommendations now that two additional vaccines PNEU-C-15 and PNEU-C-20 approved. Source: https://www.canada.ca/en/publichealth/services/immunization/national-advisory-committee-onimmunization-naci/public-health-level-recommendations-usepneumococcal-vaccines-adults-including-use-15-valent-20-valentconjugate-vaccines/summary-february-2023.html



National Immunization Strategy Goals



Flu vaccine uptake: \geq 65 years old

Flu vaccine uptake: 18-64 years old with chronic medical conditions

80%



Pneumo vaccine uptake: \geq 65 years old



Source: https://www.canada.ca/en/public-health/services/immunization-vaccine-priorities/national-immunization-strategy/vaccination-coverage-goals-vaccine-preventable-diseases-reduction-targets-2025.html#1.0

Effort to Improve Vaccination Rates Urgently Needed

2016/17



Flu vaccine uptake: \geq 65 years old Flu vaccine uptake: 18-64 years old with chronic medical conditions

Year

2018/19

2017/18

2019/20

2020/21



Pneumo vaccine uptake: <u>></u>65 years old



Source: https://www.canada.ca/en/public-health/services/immunization-vaccine-priorities/national-immunization-strategy/vaccination-coverage-goals-vaccine-preventable-diseases-reduction-targets-2025.html#1.0

The CLSA Is a Unique Resource for Characterizing Vaccine Uptake

- CLSA can provide a comprehensive assessment of patterns of vaccine uptake for influenza and pneumococcal vaccines
- Data from FU1 (2015-2018) can be used as a baseline to monitor progress towards these national immunization strategy goals
- Can identify those least likely to be vaccinated among a large cohort where numerous potential risk factors for non-vaccination have been systematically evaluated and develop strategies to support vaccination uptake among these individuals



Our CLSA Vaccine Study Aims

Characterize flu vaccine uptake & factors associated with non-vaccination:

Adults aged 65 and older

Adults aged 46-64 with at least one CMC

Caregivers (all ages) and care recipients (65 years and older)

Characterize pneumo vaccine uptake & factors associated with non-vaccination:

Adults aged 65 and older

lian Longitudinal Study on Aging longitudinale canadienne sur le vieillissement

Adults aged 47-64 with at least one CMC

Assess missed opportunities for pneumococcal vaccination



Today's Seminar



Nicole E. Basta Associate Professor School of Population and Global Health McGill University

Importance of Adult Vaccination and Insight from the CLSA

Canadian Longitudinal Study on Aging Étude longitudinale canadienne sur le vieillissement



Katie Gravagna PhD student Gillings School of Global Public Health University of North Carolina at Chapel Hill

> CLSA Flu Vaccine Uptake Study



CLSA Pneumococcal Vaccine Uptake Study

Influenza Vaccine Uptake Among Canadian Adults

Katie Gravagna, MSc

CLSA Webinar | June 7, 2023

Estimate the prevalence of influenza non-vaccination and associated factors between 2015-2018 in:

Those at high risk of severe outcomes

- 1. Adults aged 65 years and older
- 2. Adults aged 46-64 years with at least one Chronic Medical Condition (CMC)

Caregivers and care recipients

- **1.** Caregivers aged 45 years and older
- 2. Care recipients aged 65 years and older

- Cross-sectional secondary analysis of FUP1 data
- Only variables within **both** the Comprehensive and Tracking cohorts included
- Cohorts combined for analyses
- Inclusion criteria: valid response to outcome variable (self-reported influenza vaccination)
- Sensitivity analysis to see if responses changed by flu season period
- Variables chosen *a priori*
- Use of nested multivariable logistic regression models

Influenza Vaccine Uptake Among High-Risk Canadian Adults

Participants

• **51.8%** of FUP1 participants

Prevalence of influenza non-vaccination

- **29.5%** (95% CI: 28.9%, 30.1%)
- High in current daily smokers, those with higher self-rated health status, Quebec residents

Factors associated with influenza non-vaccination

- Those aged 64-74 compared to those aged 85-94 (aOR: 2.12, 95% CI: 1.82, 2.45)
- Those who **identified as non-white** compared to those who identified as white (**aOR: 1.44**, 95% CI: 1.22, 1.71)
- Lower odds: had visited a family doctor (aOR: 0.48, 95% CI: 0.42, 0.54) or specialist (aOR: 0.79, 95% CI: 0.74, 0.85) in past 12 months

Participants

• **25.1%** of FUP1 participants

Prevalence of influenza non-vaccination

- **50.4%** (95% CI: 49.4%, 51.3%)
- Did not differ by CMC type
- Prevalence was high as age decreased, for current daily smokers, and for Quebec residents

Factors associated with influenza non-vaccination

- Highest odds for Quebec residents (aOR: 2.21, 95% CI: 1.95, 2.51)
- Residence in rural areas (aOR: 1.30, 95% CI: 1.15, 1.46)
- Reported **1 CMC** (**aOR: 1.23**, 95% CI: 1.05, 1.43)
- Lower odds: had visited a family doctor (aOR: 0.53, 95% CI: 0.45, 0.62) or specialist (aOR: 0.78, 95% CI: 0.72, 0.85) in past 12 months

- High-risk groups remained well below the 2003 target of 80% coverage
- Variation in non-vaccination prevalence by province
 - Impact of universal vaccination recommendations, policies, barriers
- Importance of healthcare encounters
 - Influence of practitioner recommendations
- Expanding risk messaging
 - Younger adults with CMC
- Future studies
 - Impact of frailty on vaccination status

Influenza Vaccine Uptake Among Caregivers and Care Recipients

Participants

• **53.0%** of FUP1 participants

Prevalence of influenza non-vaccination

- **41.4%** (95% CI: 40.8%, 42.0%)
- Decreased with age
- High in residents of Quebec and those with 2+ household members

Factors associated with influenza non-vaccination

- Those who **identified as non-white** (**aOR: 1.42**, 95% CI: 1.22, 1.65)
- Current daily smokers (aOR: 1.44, 95% CI: 1.25, 1.65)
- Lower odds: had visited a family doctor (aOR: 0.53, 95% CI: 0.47, 0.59) or specialist (aOR: 0.81, 95% CI: 0.76, 0.86) in past 12 months

Participants

• **12.5%** of FUP1 participants

Prevalence of influenza non-vaccination

- **24.8%** (95% CI: 23.7%, 26.0%)
- **Did not vary** by CMC type or self-rated health
- **Decreased** as household income increased

Factors associated with influenza non-vaccination

- Younger age (65-74 years compared to older ages)
- Those who **identified as non-white** (**aOR: 2.04**, 95% CI: 1.39, 2.99)
- Current daily smokers (aOR: 1.46, 95% CI: 1.06, 1.99)
- Lower odds: had visited a family doctor (aOR: 0.61, 95% CI: 0.41, 0.90) or specialist (aOR: 0.71, 95% CI: 0.59, 0.86) in past 12 months

- Influenza vaccination remained low among caregivers at risk of transmission
- Educate caregivers
 - Direct and indirect benefits to themselves and their care recipients
- Importance of provider contact
 - Targeting influenza vaccination recommendations to those without healthcare encounters
- Modifiable risk factors: provider contact and smoking status

- Influenza non-vaccination prevalence remains high
- Identify opportunities for education
 - Younger adults
 - Those with CMC
 - Caregivers
 - Undervaccinated groups
 - Individuals without healthcare visits

- Generalizability
 - Community-dwelling adults
 - Higher education and socioeconomic status
 - Excluded some groups
- Self-reported variables
 - Outcome variable
- Missing information
 - Reasons for non-vaccination
 - Professional caregiver status
 - Vaccination trends over time

- Large sample size
 - Increased precision
- Province-level estimates
 - Explore potential barriers
- Wide range of covariates
 - Associations across many domains
 - Expand on prior studies

Contacts

- Katie Gravagna (kgrava@unc.edu)
- Dr. Nicole Basta (<u>nicole.basta@mcgill.ca</u>)

Study Team

- Katie Gravagna
- Dr. Christina Wolfson
- Dr. Giorgia Sulis
- Dr. Sarah A. Buchan
- Dr. Shelly McNeil
- Dr. Melissa K. Andrew
- Dr. Jacqueline McMillan
- Dr. Susan Kirkland
- Dr. Nicole E. Basta

University of North Carolina at Chapel Hill

- McGill University
- University of Ottawa
- University of Toronto
- , Dalhousie University
- Dalhousie University
- University of Calgary
- Dalhousie University
- McGill University

Acknowledgements

This research was made possible using the data collected by the Canadian Longitudinal Study on Aging (CLSA). Funding for the Canadian Longitudinal Study on Aging (CLSA) is provided by the Government of Canada through the Canadian Institutes of Health Research (CIHR) under grant reference: LSA 94473 and the Canada Foundation for Innovation, as well as the following provinces, Newfoundland, Nova Scotia, Quebec, Ontario, Manitoba, Alberta, and British Columbia. This research has been conducted using the CLSA dataset Baseline Tracking Dataset—Version 3.7, Baseline Comprehensive Dataset—Version 6.0, Follow-up 1 Tracking Dataset—Version 2.2, and Follow-up 1 Comprehensive Dataset—Version 3.0, under Data Access Application Number 20060290. The CLSA is led by Drs. Parminder Raina, Christina Wolfson and Susan Kirkland. The opinions expressed in this manuscript are the author's own and do not reflect the views of the Canadian Longitudinal Study on Aging.

Funding

This work was undertaken, in part, thanks to funding from the Canada Research Chairs (CRC) Program (PI: Dr. Nicole E. Basta, CRC in Infectious Disease Prevention [Tier 2]) and from the US National Institute of Allergy And Infectious Diseases of the National Institutes of Health (Award Number R01AI132496 [PI: Dr. Nicole E. Basta]). The content is solely the responsibility of the authors and does not necessarily represent the official views of any funding agency. The funding source had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Today's Seminar



Nicole E. Basta Associate Professor School of Population and Global Health McGill University

Importance of Adult Vaccination and Insight from the CLSA 2

Katie Gravagna PhD student Gillings School of Global Public Health University of North Carolina at Chapel Hill

> CLSA Flu Vaccine Uptake Study



Assistant Professor Faculty of Medicine University of Ottawa

CLSA Pneumococcal Vaccine Uptake Study

Canadian Longitudinal Study on Aging Étude longitudinale canadienne sur le vieillissement



Pneumococcal vaccination uptake among Canadian adults

Giorgia Sulis, MD PhD

Assistant Professor School of Epidemiology and Public Health | University of Ottawa



Check out our study!

PLOS ONE

RESEARCH ARTICLE

* · · · · · ·

Pneumococcal vaccination uptake and missed opportunities for vaccination among Canadian adults: A cross-sectional analysis of the Canadian Longitudinal Study on Aging (CLSA)

Check for updates Giorgia Sulis^{1*}, Valérie Rodrigue¹, Christina Wolfson^{1,2,3}, Jacqueline M. McMillan^{4,5}, Susan A. Kirkland^{6,7}, Melissa K. Andrew⁷, Nicole E. Basta¹

1 Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada, 2 Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada, 3 Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4 Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, 5 O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada, 6 Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada, 7 Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada



G OPEN ACCESS

Study objectives

- (1) Estimate self-reported pneumococcal vaccine uptake and differences in uptake among Canadian adults eligible to be vaccinated
 - \succ adults aged ≥ 65
 - adults aged <65 with at least one underlying medical condition</p>
- (2) Identify **factors associated** with pneumococcal non-vaccination
- (3) Assess the frequency and determinants of **missed opportunities** for vaccination

Data source



https://www.clsa-elcv.ca



Variables in brief

OUTCOMES

Lack of pneumococcal vaccination (self-reported)

2) Missed opportunity for pneumococcal vaccination

Sociodemographic

characteristics

Chronic medical conditions

Contact with family doctor in prior year

Receipt of flu shot in prior year

COVARIATES

Sulis G et al, PLOS ONE 2022

1)

Analysis

- Separate analyses for
 - 1) adults aged 65+
 - 2) adults aged 47-64 with chronic conditions
- Descriptive analysis of (self-reported) pneumococcal vaccine uptake across subgroups defined by covariates of interest
- Multivariable logistic regression for associations between lack of pneumococcal vaccination and a range of covariates
- Evaluation of missed opportunities for vaccination (more soon)

Pneumococcal vaccine uptake among adults aged 65+

54.2% reported having received a pneumococcal vaccine

Who is more likely to be non-vaccinated among adults aged 65+?



Pneumococcal vaccine uptake in adults aged 65+ increases with...

- o age
- o income
- residence in MB, SK, QC...
- \circ having at least 1 chronic condition
- o receipt of influenza vaccine in past 12 months
- o contact with family doctor in past 12 months

Pneumococcal vaccine uptake among adults aged 47-64 with one or more chronic conditions

18.7% reported having received a pneumococcal vaccine

Who is more likely to be non-vaccinated among adults aged 47-64?

People with higher income



Those residing in NL



Pneumococcal vaccine uptake in adults aged 47-64 increases with...

o age

receipt of influenza vaccine in past 12 months

o contact with family doctor in past 12 months

Lots of missed opportunities for vaccination



"Any contact with health services by an individual (child or person of any age) who is eligible for vaccination (e.g. unvaccinated or partially vaccinated and free of contraindications to vaccination), which **does not result** in the person receiving one or more of the vaccine doses for which he or she is eligible." (WHO definition)

Lots of missed opportunities for vaccination

2 TYPES OF MISSED OPPORTUNITY CONSIDERED:

- \rightarrow Receipt of influenza vaccine
- \rightarrow Contact with family doctors

Males (vs. females) and **residents of Atlantic provinces** (vs. ON) more likely to miss an opportunity for pneumococcal vaccination



Missed opportunity in >32% of adults aged 65+ who received an influenza vaccine in the previous 12 months



Missed opportunity in >70% of adults aged 47-64 with chronic conditions who received an influenza vaccine in the previous 12 months



Missed opportunity in ~45% of adults aged 65+ who had contact with a family doctor in the previous 12 months



Missed opportunity in >80% of adults aged 47-64 with chronic conditions who had contact with a family doctor in the previous 12 months

Sulis G et al, PLOS ONE 2022

PNEUMOCOCCAL VACCINATION

Strengths

- Largest cohort of adults in Canada
- Participants from 10 provinces
- Provides excellent estimate of vaccine uptake among various subgroups

Limitations

- Data collected prepandemic
- Cross-sectional data → no time trends
- Self-reported vaccination status
- No data on reasons for getting or not getting vaccinated

Main take-aways

- Pneumococcal vaccine uptake remains below expectations among at-risk adults in Canada
- Awareness about pneumococcal vaccines likely low among highrisk groups
- Substantial heterogeneity in pneumococcal vaccine uptake among Canadian provinces → differences in vaccination programs
- Efforts needed to reduce missed opportunities for vaccination

Study team

Giorgia **SULIS**, University of Ottawa Valérie **RODRIGUE**, McGill University Christina **WOLFSON**, McGill University Jacqueline M. **MCMILLAN**, University of Calgary Susan A. **KIRKLAND**, Dalhousie University Melissa K. **ANDREW**, Dalhousie University Nicole E. **BASTA**, McGill University

<u>CONTACTS</u>: Dr. Giorgia Sulis (<u>gsulis@uottawa.ca</u>) Dr. Nicole Basta (<u>nicole.basta@mcgill.ca</u>)



Acknowledgements:

This research was made possible using the data collected by the Canadian Longitudinal Study on Aging (CLSA). Funding for the Canadian Longitudinal Study on Aging (CLSA) is provided by the Government of Canada through the Canadian Institutes of Health Research (CIHR) under grant reference: LSA 94473 and the Canada Foundation for Innovation, as well as the following provinces, Newfoundland, Nova Scotia, Quebec, Ontario, Manitoba, Alberta, and British Columbia. The CLSA is led by Drs. Parminder Raina, Christina Wolfson, and Susan Kirkland. The opinions expressed in this manuscript are the author's own and do not reflect the views of the Canadian Longitudinal Study on Aging.

CLSA Datasets:

- CLSA Baseline Data Version 3.7 (tracking cohort) and 6.0 (comprehensive cohort)
- CLSA follow up 1 Data Version 2.2 (tracking cohort) and 3.0 (comprehensive cohort)

Funding sources:

This work was supported by research funds from the Canada Research Chair (CRC) program (<u>https://www.chairs-</u> <u>chaires.gc.ca/program-programme/index-eng.aspx</u>) [PI: Nicole E. Basta, CRC in Infectious Disease Prevention (Tier 2)]. Research reported in this publication was also supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health (<u>https://www.niaid.nih.gov</u>) under Award Number R01AI132496 (PI: Dr. Nicole E. Basta). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Summary: Pattens of Vaccine Uptake

- The CLSA has provided significant insight into detailed pattens of vaccine uptake among Canadian adults from 2015-2018 (Follow-up 1)
- The comprehensiveness of the CLSA data allowed us to go beyond routine national vaccination coverage surveys and investigate multiple factors simultaneously to better understand who is missing out on flu and pneumo vaccine uptake among Canadian adults



Summary: Caregivers/recipients and Missed Opportunities

- We took the opportunity to focus on two understudied groups who would benefit significantly from flu vaccination: caregivers & care recipients
- We also assessed missed opportunities for pneumo vaccination
- Both of these aspects of our analyses plus the descriptive results provided greater insight into who may benefit most from interventions to improve uptake



nicole.basta@mcgill.ca

58

Next Steps

- Continue to learn from the CLSA by assessing Influenza, pneumococcal, and shingles uptake using Follow-up 2 (FU2) data
- Compare changes over time and refine hypotheses about factors associated with non-vaccination
- Use the evidence from our CLSA analyses to design and then evaluate the impact of targeted interventions intended to improve uptake among those with low vaccination rates who may benefit most

Build on the evidence from our CLSA analyses to better understand reasons for low vaccine uptake and to identify barriers to vaccination in future studies n Longitudinal Study on Aging longitudinale canadienne sur le vieillissement nicole.basta@mcgill.ca

59

Thank you!

All CLSA participants who have given so generously of their time and from whom we have learned so much. Everyone who has made the CLSA a success including PIs, Study Coordinators, Study Staff, Data Curators, Analysts, and Support Staff. All of our collaborators with whom it has been a pleasure to conduct this research.



Ø∰ ⊉′ ★ Vipfr

VACCINES, INFECTIOUS DISEASE PREVENTION & EPIDEMIOLOGY RESEARCH GROUP The VIPER Group aims to advance our understanding of infectious disease epidemiology, to prevent and control the spread of disease, and to promote health and well-being worldwide. PI: Nicole Basta, PhD MPhil